Why the study?
Does monitoring fibrinopeptide A (FPA) levels during heparin therapy reflect disease activity and resolution in patients with venous thromboembolism?
Population
51 patients with thromboembolism (including 15 with concurrent sepsis or malignancy)
Comparison
Heparin therapy with monitoring of… vs Patients with minimal resolution vs marked…
Design
Cohort
Follow-up
during heparin treatment
Authors
Loading...
FPA levels may reflect resolution during heparin in isolated thromboembolism; leaves open prospective validation before guiding monitoring.
Does monitoring fibrinopeptide A (FPA) levels during heparin therapy reflect disease activity and resolution in patients with venous thromboembolism?
FPA levels may serve as a useful biomarker for monitoring disease activity and resolution in venous thromboembolism during heparin therapy, provided there is no coexisting sepsis or malignancy.
Yudelman et al. (1982) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: